Biagio Ricciuti, MD PhD @BiagioRicciutMD Twitter profile

Last Seen Profiles

@cortlluminati

@leitijoelsene

@Crypto_boyzman

@iv_knowle

@ZySkeezy

@xxiamoon

@MrMatthewfixed1

@feari_oze

@binor40

@MariaaRamirezz

@yasosuke426

@69rus1

@RumblyF

@JasonHu81359739

@haku010218

@posbar46

@aleksandr_lanne

@DavidJHarrisJr9

@aruaru5353

@StellaPerks

@srSlyR6

@Big__OJ

@Hamster_Combo

@finisher65

@eat_predators

@Lucrebasaglia

@glenweyl

@albasman13

@jakkystealurgrl

@aurin_4

@tnmntna

@AmelieBonT

@ismailbalaban7

@rrrsss789d

@TubaTavac11

@theblockwhale

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

KEAP1 mutations (mut) are heterogeneous in lung adenocarcinoma (LUAD). In this study out in @Annals_Oncology we found that clonal KEAP1 mut w/ LOH have unique transcriptomic & immunophenotypic features, and are associated w/ #ICI resistance @OncoAlert 1/7

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low...

KEAP1 mutations have been associated with reduced survival in lung adenocarcinoma (LUAD) patients treated with immune checkpoint inhibitors (ICIs), particularly in the presence of STK11/KRAS altera...

www.annalsofoncology.org

2

36

104

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

#KRASmt (mutated) cancers are heterogenous. In this study out in @Annals_Oncology we examined clinicopathologic, genomic, and immunophenotypic features of KRAS G12D NSCLC from four major academic centers. #lcsm @DanaFarberNews @KRASKickers Link: 1/7

6

30

104

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 months

🚨Our collaborative effort to characterize #MET kinase domain mutations as novel & targetable alterations in #NSCLC and other cancer types is out in @CD_AACR ! Led by💫scientists @pecci_federica1 & Seshiru Nakazawa @DanaFarberNews @OncoAlert #LCSM 1/4🧵

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung...

Abstract. Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling among >600,000...

aacrjournals.org

7

26

96

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

🚨Fusion partners and chromosomal breakpoints of oncogenic fusions involving #ALK , #ROS1 , #RET and #NTRK1 are not stochastic! Out in @NatureComms our study demonstrating that typical #TK fusions are selected from pools of chromosomal rearrangements by two major determinants:

3

22

93

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC . Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao . #biomarkers can help⬆️outcomes. @OncoAlert #LCSM

0

21

81

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

7 months

🚨Out in @JCO_ASCO our work dissecting the genomic & immunophenotypic correlates of acquired resistance (AR) to PD-(L)1 blockade in #NSCLC . @OncoAlert #LCSM @DanaFarberNews @ASCO @IASLC Link: 1/9

5

27

83

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Deeply grateful to be nominated and selected for the 2023 class of #40 under #40 Rising Stars and Emerging Leaders in #Cancer ! Looking forward to meeting all the awardees in #Chicago at #ASCO23 ! @DanaFarber @harvardmed #LCSM

4

8

80

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Great international effort lead by @mihaela_aldea from @GustaveRoussy examining clinical characteristics, genomics, and outcomes of patients with #NSCLC and #RET fusions. #AACR22 @BenjaminBesseMD

3

12

71

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 years

Important study on the correlation between tumor aneuploidy and immunotherapy efficacy in NSCLC presented by my dear friend and wonderful scientist ⁦ @alessi_joao ⁩ at #SITC2021 ⁦ @DrMarkAwad ⁩ ⁦ @DanaFarber ⁩ ⁦ @sitcancer ⁩

3

10

67

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 months

If you are at #AACR24 , stop by poster 21 (section 1) to learn more about the discovery of #ALK -specific #TCR clonotypes for the development of TCR-T cell therapies against ALK-positive cancers! Amazing study led by @CarmenMeccaPhD . @BostonChildrens @harvardmed @ALKpositiveINT

7

6

64

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 years

Wonderful collaboration with @AmbrogioLab to characterize #KRAS isoforms in NSCLC. Grateful to my talented colleagues @XinAnnWang , @alessi_joao , and mentor @DrMarkAwad at @DanaFarber . @CCR_AACR @DanaFarberNews

3

11

63

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Our study on the genomic landscape of RAS mutant tumors is out in @CR_AACR 🚨. We dissected the genomic profiles of mutant #RAS alleles to identify cancer lineage-specific therapeutic vulnerabilities. W/ the phenomenal @ValsamoA @christine_lovly @DrMarkAwad @OncoAlert @AACR

Cancer Research

@CR_AACR

2 years

Analysis of NGS data from 66,372 tumors and 51 cancer types from @AACR Project GENIE reveals the complex genomic landscape of #RAS mutant tumors and highlights lineage-specific differential vulnerabilities. @BiagioMd @DrMarkAwad @christine_lovly @ValsamoA

0

18

52

1

23

63

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Comprehensive mutational scanning of #EGFR reveals TKI sensitivities of extracellular domain mutants. 🧬Multiple EGFR extracellular domain variants, not associated with approved targeted therapies, were sensitive to afatinib and dacomitinib in vitro.

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants

Nature Communications - EGFR mutations are frequent in glioblastoma and lung cancer. Here, the authors perform deep mutational scanning of EGFR, followed by a high-throughput functional screen and...

www.nature.com

2

23

60

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 years

Congrats to our outstanding mentor @DrMarkAwad on being named by @clarivate among the 1% most cited scientists in the world. His dedication, compassion, and transformative science are inspiring a whole generation of young researchers in their fight against cancer. @alessi_joao

Dana-Farber News

@DanaFarberNews

3 years

Congratulations to the 24 Dana-Farber researchers who were recognized today by @clarivate as the among the most highly cited researchers worldwide. #HighlyCited2021

0

9

59

3

8

58

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Thanks @CCR_AACR for featuring our work on the clinico-genomic landscape of #ATM mutations in #NSCLC on this month’s cover! W/ @ArielleElkrief @alessi_joao @XinAnnWang @DanaFarberNews @MSKCancerCenter @OncoAlert #LCSM Read more about this effort here:

1

10

55

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 month

Thrilled to receive a 2024 @IASLC #YIA to develop new therapies for #KRAS amplified #NSCLC . Grateful for the support and excited to work towards better treatments for our patients. w/ @AmbrogioLab , @DrMarkAwad & many wonderful collaborators! @KRASKickers @DanaFarberNews #LCSM

Dana-Farber News

@DanaFarberNews

1 month

Congratulations to @danafarber BiagioRicciuti, MD, PhD ( @BiagioRicciutMD ) who is a recipient of the @IASLC 2024 Young Investigator Grant for his work: Targeting KRAS amplification as a de novo oncogene driver alteration in non-small cell lung cancer. More▶️

6

10

63

6

65

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC . w/ a stellar faculty @JordiRemon @peters_solange @PassigliaFra @ChristianRolfo , @TonyMok9 @StephenVLiu , @fred_hirsch @FedericoCappuz1 @RobertoFerrara_ @BenjaminBesseMD &

Stephen V Liu, MD

@StephenVLiu

3 months

Dr. @BiagioRicciutMD summarizes immunotherapy biomarkers at #RomeLung24 . PDL1 expression is still our best biomarker: higher the better. TMB plays a role but higher cutoffs predict better. STK11/KEAP1 predict poor outcomes with PDL1 but targeting CTLA4 can potentially overcome.

0

9

44

1

9

52

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

5 months

“A good #mentor is someone who has more imagination about you than you have about yourself”. There’s no better description for my former mentor Prof Crinò. It was wonderful to share the stage with him years later, discussing resistance mechanisms to targeted therapies in #NSCLC .

5

3

48

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Glad to see this multicenter collaborative effort out in @CD_AACR today. Co-mutations impact #KRAS G12Ci efficacy in #NSCLC . Led by @mvnegrao @GLambertiMD @alissajcooper @DrMarkAwad @FSkoulidis and many others. @OncoAlert @AACR @DanaFarber @MDAndersonNews

2

15

47

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Important effort to out in @NatureComms characterizing FAK-YAP signaling as mediator of residual disease during targeted therapies in #NSCLC . ✅FAK-YAP inhibition + targeted therapy 💊 combo suppresses residual drug-tolerant cells. 🚨🚨 @OncoAlert #LCSM

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease...

Nature Communications - Remaining drug-tolerant persistent (DTP) cancer cells limit the efficacy of targeted therapy in EGFR, ALK and KRAS mutant non-small cell lung cancer (NSCLC). Here, the...

www.nature.com

1

11

47

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 months

🚨Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in #NSCLC is out in @JTOonline . PD-L1 TPS ≥90% (vs 50-89%) is associated w/⬆️3-year PFS and OS rates and favorable genomic & immunophenotypic profiles. #LCSM @IASLC 🧵1/10

3

14

45

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

🚨High aneuploidy and chromosome 9p loss by NGS are associated with lower CD8+ T cells and less favorable outcomes to #ICIs in #NSCLC . Out in @JTOonline our multicenter effort co-led by the trio @alessi_joao @XinAnnWang @ArielleElkrief #LCSM @OncoAlert

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint...

Although gene-level copy number alterations have been studied as a potential biomarker of immunotherapy efficacy in NSCLC, the impact of aneuploidy burden and chromosomal arm-level events on immune...

www.jto.org

3

15

44

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Our multicenter study on the clinico-genomic and immunophenotypic landscape of #ATM mutations in #NSCLC is out in @CCR_AACR 🚨. w/ @ArielleElkrief , @alessi_joao , @XinAnnWang , @DrMarkAwad , @AdamJSchoenfeld & #MichaelCheng @DanaFarberNews @OncoAlert #LCSM 1/8

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung...

AbstractPurpose:. ATM is the most commonly mutated DNA damage and repair gene in non–small cell lung cancer (NSCLC); however, limited characterization has been pursued.Experimental Design:. Clinico...

aacrjournals.org

1

14

44

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Gefitinib + chemotherapy combo continues to show ⬆️PFS & OS at 5y of follow-up vs gefitinib monotherapy in #EGFR + #NSCLC . 5-year OS: 13% vs 4.4% (HR, 0.58). 5-year PFS: 6.7% vs 1.7% (HR, 0.53). Implications for countries with limited access to 3rd gen TKIs 🚨🚨 @OncoAlert #LCSM

JAMA Oncology

@JAMAOnc

3 months

Progression-free survival and overall survival benefits of adding chemotherapy to gefitinib were sustained at 5 years, confirming earlier results reported at median follow-up of 17 months.

1

22

53

1

13

44

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

8 months

Had a great time and thoughtful conversations on the current & future role of ADCs in #NSCLC w/ terrific Brazilian colleagues and friends in San Paolo 🇧🇷. Thanks for hosting @MarceloCorassa @alessi_joao @HaradaGuilherme @gustavoschv @helanofreitas @RicardoZyll Luiz Araujo #DASA

3

7

42

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

8 months

Terrific effort out in @Cancer_Cell led by @ElisaBergaggio ( #AICF awardee), w/ @CarmenMeccaPhD ( @AIRC_it awardee), @AmbrogioLab , and many others! Combination of #ALK TKIs with ALK.CAR-Ts is a potent therapy for neuroblastoma. @BostonChildrens @chiarlelab

1

7

42

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

11 months

Congratulations to @GLambertiMD and the study team on completing this investigator initiated, multicenter, ph2 study of atezolizumab and bevacizumab in combination with platinum/etoposide in pts with extensive #SCLC . 1-year OS 61.8%, mPFS 6.2 months. #WCLC2023 @Unibo

1

10

40

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Thanks @ASCO for highlighting our effort to identify genomic correlates of acquired resistance to immunotherapy in #NSCLC . Grateful to @sitcancer for supporting this study! #ASCO22 @DanaFarberNews @OncoAlert @DrMarkAwad

Improving Outcomes in NSCLC: Understanding the Mechanisms of Resistance to ICIs and Expanding...

Despite drastic improvement in survival brought on by the approval of immune checkpoint inhibitors (ICIs) for non–small cell lung cancer (NSCLC), less than 50% of patients with advanced NSCLC do not...

dailynews.ascopubs.org

1

10

40

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Machine learning-based assessment of TILs on H&E slides can help predicting #immunotherapy efficacy in #NSCLC . Great multi-institutional effort out in @JAMAOnc w/Mehrdad Rakaee, @adib_elio @ACortelliniMD @alessi_joao & many others. @OncoAlert @DanaFarber

1

10

39

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

🚨Out in @JAMAOnc our effort to determine the association of automatically extracted body composition metrics with #immunotherapy efficacy in patients with metastatic #NSCLC . 👉Skeletal muscle loss & changes in subcutaneous adipose tissue are important dynamic prognostic

1

13

36

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

11 months

Thanks @OncLive for the opportunity to review the results of our analysis on the 3-year outcomes to PD-1 monotherapy in pts with NSCLC and a PD-L1 of 50-89% vs >90% at #WCLC23 in Singapore 🇸🇬. To learn more about this effort join us tomorrow at 2.30 pm (405A)! @DanaFarber @IASLC

OncLive.com

@OncLive

11 months

Thanks to @BiagioRicciutMD , of @DanaFarber , for joining us at #WCLC23 to talk about first-line pembrolizumab in patients with NSCLC and a TPS > 90%! Head to our site to see more meeting insights! @IASLC #lcsm

0

12

1

4

37

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

Thanks @Annals_Oncology for featuring our review on how to optimize the use of #TMB for predicting #ICI efficacy on this month’s cover. @myESMO Here we reviewed challenges & opportunities for TMB & immunotherapy focusing on: -Technical limitations 🔬 -Spatial & temporal

Annals of Oncology

@Annals_Oncology

2 months

June issue of Ann Oncol now online ⏺️ESMO CPG update on 1st line therapy in adv urothelial carcinoma ⏺️review on Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer ⏺️ 5-year results from CheckMate 040 trial in HCC And more

1

3

15

4

14

37

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Thanks ⁦ @medpagetoday ⁩ for highlighting our study in ⁦ @CCR_AACR ⁩ examining the heterogeneity of #KRAS variants in #NSCLC . ⁦ @AmbrogioLab ⁩ ⁦ @DanaFarberNews ⁩ ⁦ @OncoAlert ⁩ ⁦ @unito ⁩

Therapeutic Vulnerabilities of KRAS Mutations in NSCLC - Advances in mNSCLC

The results of an international study suggest that using specific genetically defined in vitro tools and patient-derived data sets will help researchers identify potentially actionable vulnerabilit...

www.medpagetoday.com

3

13

36

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

D3S-001, a next generation GDP-bound #KRAS G12C inhibitor demonstrates robust preclinical and clinical activity. ✅Rapid target engagement ✅Active KRAS G12C depletion at nanomolar concentrations ✅Kinetics nearly unaffected in presence of growth factors (e.g. EGF/HGF) (vs

1

7

35

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

6 months

🚨Out in the @OncJournal our pooled analysis of 11 PD-(L)1 monotherapy clinical trials quantitating the effect of increasing PD-L1 expression on outcomes in #NSCLC . w/ @FDAOncology @jonjvallejo , @harpreet_md , @DrMarkAwad . @DanaFarberNews @OncoAlert #LCSM

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A...

Previous studies have shown that outcomes in patients with non–small cell lung cancer treated with anti-PD(L)1 inhibitors generally improve with increasing

academic.oup.com

2

9

35

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Great collection of articles from @AACR journals on the recent developments in targeting #KRAS , featuring our 2 studies on the hallmarks & vulnerabilities of #RAS isoforms in cancer. W/ stellar investigators @ValsamoA @AmbrogioLab @OncoAlert @DanaFarber

1

7

33

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

“Someday, I don't know when We're gonna get to that place Where we really wanna go and we'll walk in the sun But 'til then, tramps like us we were born to run…” @CarmenMeccaPhD #tdgarden #springsteen

1

33

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

5 years

Among patients with NSCLC and a PD-L1 expression of ≥50%, clinical outcomes to 1st-line pembrolizumab improve with increasing PD-L1 cut-offs. #oncoalert #lcsm @Annals_Oncology @DanaFarber

Mark Awad

@DrMarkAwad

5 years

How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online @Annals_Oncology @BiagioMD @Elizabethjimag @DanaFarber

2

50

103

1

8

33

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

I had a great conversation with the amazing @NarjustFlorezMD and @SchenkLab on the role of #ICI in patients with #NSCLC and driver mutations. The potential of immune therapies has yet to be realized for most of oncogene-positive lung cancers. We need to explore options beyond

Narjust Florez, MD, FASCO

@NarjustFlorezMD

2 months

I hope you are ready for this discussion with Drs. @SchenkLab & @BiagioRicciutMD I learned SO much only in the first 5 minutes of this conversation about the use of IO in patients with NSCLC and driver mutations. Including -Toxicity -Importance of NGS -Prognostic and

1

4

26

2

11

33

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

Couldn’t agree more!! @Arushi03Saini is talented and compassionate med student. Her work will be instrumental to understanding the correlates of response to #immunotherapy in #NSCLC with STK11/KEAP1/SMARCA4 mutations. @harvardmed @DanaFarber . More on this at #WCLC24 @IASLC .

Udhayvir Grewal

@UGrewalMD

2 months

I was blown away by the masterful presentation on IO outcomes in lung cancer by Arushi Saini, med student and research fellow @DanaFarber . I had to ask her twice if she wasn’t lying about not being a thoracic oncologist 😅Truly inspired 🏆 ! @BiagioRicciutMD @DrMarkAwad #ASCO24

0

4

22

0

8

31

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Happy birthday to my dear friend and awesome scientist @alessi_joao !! I feel incredibly fortunate to have crossed paths with you! @PTarantinoMD @CarmenMeccaPhD @darioT_ @BarrichelloMd @pecci_federica1 @BarrichelloMd @victorrvaz @XinAnnWang @PatPag

Paolo Tarantino

@PTarantinoMD

2 years

The true meaning of TMB: The Masterchef of Brookline! Whose cooking skills are only second to his pace of publication Mr. @BiagioMd !👨‍🍳

3

39

4

5

31

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

11 months

Insightful presentation by our ⭐️ fellow and soon to be thoracic oncologist @DiFedericoMD , on the impact of TTF-1 expression on clinical outcomes in #LUAD at #WCLC2023 . Negative expression (~15%) associates with ⬇️ PFS and OS to ICI +/- CT, and KRAS G12Ci. @DanaFarberNews @IASLC

1

2

32

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

9 months

🚨🚨Wild-type RET amplification represents a potentially targetable subset of cancer. This report by our stellar med student @malini_gandhi shows these alterations can be seen across cancers and respond to RET inhibition. @OncoAlert #LCSM @JCOPO_ASCO

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With...

PURPOSE RET rearrangements and RET activating point mutations represent targetable genomic alterations in advanced solid tumors. However, the frequency and clinicopathologic characteristics of...

ascopubs.org

1

10

30

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 month

Neoadjuvant SHR-1701 (fusion protein targeting PD-L1 & TGFβ) +/-chemotherapy in unresectable stage III #NSCLC . Ph 2 ORR 58%; 18-month EFS 56.6%. Surgery conversion: 25%, w/ 100% R0 resections Surgical set: pCR 26%, 18-month EFS 74.1% (vs. 57.3% in RT set) @OncoAlert #LCSM

0

7

26

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

5 months

Had a great time and thoughtful discussion on how to optimize treatments for lung cancer at the 2023 in Review - Lung Cancer meeting in São Paulo 🇧🇷 W/ an amazing faculty @NarjustFlorezMD @BrunaPellini and stellar oncologists @MarceloCorassa @ClaudioVladmir @HaradaGuilherme

Vladmir C. Cordeiro de Lima, MD, PhD

@ClaudioVladmir

5 months

Great discussion around treatment of metastatic 🫁 cancer at the 2023 in Review Lung Cancer. Participation of stellar experts @NarjustFlorezMD @BrunaPellini @BiagioRicciutMD and many brilliant oncologists friends! Delightful! Congratulations @MarceloCorassa !

1

5

23

1

27

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Congrats to all the 2023 @IASLC Academy awardees! Including our stellar visiting scientists @pecci_federica1 and @DiFedericoMD ! Thanks @IASLC for supporting young investigators and trainees! @marinagarassino @ChristianRolfo @DanaFarber

Christian Rolfo

@ChristianRolfo

1 year

Indeed Amy! Starting a new @IASLC Academy! Very excited to see a big multidisciplinary & motivated participants from around the world! Thanks @IASLC to support career development! @karenkellymd @HwakeleeMD thanks to the participants and great faculty!

2

3

19

2

4

28

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 years

Great study from Chiarle Lab in @BloodJournal unveiling the role of PTPN1/2 in regulating resistance to ALK inhibitors in ALCL. Thank you to @AIRC_it for supporting my wonderful wife @CarmenMeccaPhD who contributed to this important work! @BostonChildrens

2

7

27

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

10 months

Immunogenicity and sensitivity to #ICI in TMB-high GEMMs is partially dependent on p53. TP53 truncating mutations ➡️shorter survival to #ICI in #NSCLC . Out in @Cancer_Cell our collaborative effort led by the stellar @EsraAkbay_ ; w/ @utswcancer @alessi_joao @DanaFarber @OncoAlert

Cancer Cell

@Cancer_Cell

10 months

Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden

0

40

150

1

5

28

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Pembrolizumab monotx continues to improve survival at 3-years in pts with #NSCLC and PD-L1 TPS >90% vs 50-89%. Thanks to all the investigators who supported this study! @ArielleElkrief @DrMarkAwad @AdamJSchoenfeld @JustinGainor @JessicaJLinMD @OncoAlert

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of...

www.onclive.com

0

11

26

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Pooled 5y outcomes of Pembro+Chemo vs Chemo for PDL1<1% metastatic #NSCLC (KN189, KN407 + Japan/China extensions). OS HR: 0.64, PFS HR: 0.66 & 5y OS 12.5% vs 9.3% favoring Pembro+Chemo. @JTOonline @IASLC @ShirishGadgeel @marinagarassino @OncoAlert 🚨

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor...

We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic NSCLC with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) less than 1%...

www.jto.org

0

9

27

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Glad to see our collaborative effort on the predictors of long-term response to #ICI in #NSCLC out in @CCR_AACR today! W/⭐️ investigators @rohit_thum @NIVokes @AdamJSchoenfeld @DrMarkAwad @alessi_joao @ArielleElkrief @DiFedericoMD @GLambertiMD @pecci_federica1 @OncoAlert #LCSM

Rohit Thummalapalli

@rohit_thum

1 year

Our multicenter study of clinical and molecular predictors of long-term response to ICIs in advanced NSCLC is out today in @CCR_AACR ! Thanks to @AdamJSchoenfeld @BiagioRicciutMD @DrMarkAwad @NIVokes and all others for the great collaboration. 1/5

6

11

56

1

5

26

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

Phase III PALOMA3 trial of SC versus IV Amivantamab + lazertinib in refractory EGFR+ NSCLC @JCO_ASCO 🚨 @OncoAlert 🚨 ✅Similar PK outcomes (non-inferiority) 📉Fewer patients in the SC group experienced infusion-related reactions (13% vs. 66%) and VTE (9% vs. 14%) vs the

1

7

24

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Thanks @DAVAOnc for the opportunity to review strategies to optimize PD-(L)1 inhibition in #NSCLC at #DAVAHawaiiLung23 , with a stellar panel @ValsamoA @NIVokes @DeepaRangachari @JulieBrahmer @RamalingamMD #LCSM

DAVA Oncology

@DAVAOnc

1 year

(1 of 2) Starting Now: Optimizing PD-1/PD-L1 Targeting. Moderated by Valsamo Anagnostou. @ValsamoA #DAVAHawaiiLung

1

3

14

2

1

25

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by @AmbrogioLab . Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.

0

5

24

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Wonderful collaborative effort led by @aravi1 , @JustinGainor , @getz_lab to dissect the molecular determinants of response to #ICI in #NSCLC . This integrative analysis will hopefully be a resource for the community as we try to improve outcomes in NSCLC. @NatureGenet @OncoAlert

Justin Gainor

@JustinGainor

1 year

(1/3) Excited to share our work on genomic and transcriptomic predictors of response to PD-(L)1 inhibitors in NSCLC @NatureGenet ; nearly 400 pts and growing, forming the SU2C/Mark Foundation cohort

6

66

212

0

7

25

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

9 months

Great session and thoughtful discussion on mechanisms of resistance to #ICI in #NSCLC with a stellar faculty at #IO23 in Brussels 🇧🇪 @AdamJSchoenfeld , Thomas Marron, @Gmazzaschi90 . #LCSM @IASLC @DanaFarber @MSKCancerCenter @MountSinaiNYC

IASLC

@IASLC

9 months

Learn More about Primary and Acquired Resistance to PD-(L)1 Blockade in #NSCLC : A Clinical Perspective, from current #IO23 speaker @BiagioRicciutMD . #LCSM

0

9

1

23

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

Thanks @DanaFarberNews for highlighting our effort to understand what the optimal duration of #ICI should be in pts with #NSCLC . Echoing @thenasheffect , understanding how to mitigate irAEs that impact quality of life for pts on long term ICI needs to be a high priority area.

Dana-Farber News

@DanaFarberNews

2 months

Spotted at #ASCO24 : Lakshmi Nayak, MD, on the podium with #CNSLymphoma research; @AtishChoudhury speaking with @OncLive ; @ChrisManzMD with a rapid oral abstract; and @BiagioRicciutMD and @DrMarkAwad with a #LungCancer poster.

0

4

30

0

6

22

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 month

Congrats to my dear friends and collaborators @mihaela_aldea & @ACortelliniMD on receiving a 2024 @IASLC #YIA . Echoing @mihaela_aldea , 🌍 collaboration is key to advancing the field and developing better treatments for #NSCLC .

Mihaela Aldea

@mihaela_aldea

1 month

Honored to receive a 2024 @IASLC #YIA . Congrats to all awardees & friends @BiagioRicciutMD , @ACortelliniMD & others. 🌎Collaboration is key to help our patients. Thank you @IASLC #LCSM #TeamScience @GustaveRoussy @DanaFarber @BenjaminBesseMD @DrMarkAwad

6

5

52

2

3

22

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Important study out in @BloodJournal from @jdsoumerai et al. showing that next-gen #ALK inhibitors are active in ALK+ large B-cell #lymphoma . w/ @CarmenMeccaPhD from @chiarlelab at @BostonChildrens , @DanaFarber , @MSKCancerCenter , and @MGHCancerCenter

2

5

20

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 months

Thoughtful discussion by @marinagarassino on the use of liquid biopsy to guide treatment decisions for patients with #NSCLC and #EGFR mutations. #AACR24

UChicagoCancerCenter

@UCCancerCenter

4 months

Join Marina Garassino, MD, PhD ( @marinagarassino ) on a "Clinical Trials Plenary Session" today at #AACR24 .

0

3

12

1

3

21

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 months

@NIVokes @alessi_joao @XinAnnWang @DrMarkAwad @lmsholl @RobertoFerrara_ @GLambertiMD @DiFedericoMD

Emre Yekedüz

@yekeduz_emre

4 months

🔥 A must-read review pertaining to "tumor mutational burden" , which is a predictor of response to PD(L)-1 inhibition 🎯 ⭐️🔥✅Key points that should be kept in mind in terms of using TMB in clinical practice:🚨 🧬TMB is estimated using next-generation sequencing (NGS), whole

1

18

48

0

5

18

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 years

Proud to be one of the recipient of the #ASCO20 @ConquerCancerFd YIA. Huge thanks to my outstanding mentor @DrMarkAwad , for his tireless dedication to his trainees. @DanaFarber , @GRecondoMD , @GLambertiMD , @alessi_joao , @Deepti_Venkat .

Mark Awad

@DrMarkAwad

4 years

So proud of Biagio Ricciuti @BiagioMd ! His kindness, generosity, intellect, and hard work are exceptional. Thank you to the @ConquerCancerFd for supporting his research @DanaFarber with a YIA.

3

2

27

2

0

18

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

Wonderful presentation by @XinAnnWang at #AACR23 on the impact of individual level uncertainty of lung cancer polygenic risk score on risk stratification and prediction. @HarvardChanSPH @XihongLin

0

4

17

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

Congrats to our dear friend and incredibly talented scientist @XinAnnWang , Doctor in Philosophy at @HarvardChanSPH !! Ad maiora! @HarvardBiostats @alessi_joao @victorrvaz @DrMarkAwad @XihongLin #HarvardChan22

3

0

16

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

Important case study by💫 @renato_umeton et al. in @NEJM_AI reporting on the challenges and lessons learned in the deployment of large language models (LLMs) at @DanaFarber for use in basic research, clinical research, operations, & more! @OncoAlert

GPT-4 in a Cancer Center — Institute-Wide Deployment Challenges and Lessons Learned

The enormous potential for generative pretrained transformers (GPTs) and other artificial intelligence (AI) large language models (LLMs) to improve health care has become increasingly clear. Softwa...

ai.nejm.org

2

4

14

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

If you are attending #ASCO24 don’t forget to register to the 🚨 @OncoAlert 5K walk/run. June 1st, 7 AM. Start Hyatt Regency at McCormick Place, Chicago! ⬇️⬇️⬇️

OncoAlert

@OncoAlert

3 months

THE @OncoAlert 🚨5K REGISTRATION at #ASCO24 Saturday, June 1st at 7am (Chicago) Start Hyatt Regency at McCormick Place , Chicago Countries of Colleagues participating: 🇺🇸🇨🇦🇨🇭🇹🇷🇮🇹🇧🇪🇸🇪🇲🇽🇱🇧🇵🇹🇫🇷🇲🇦🇦🇹🇭🇺🇸🇰🇮🇳🇩🇪🇮🇪🇳🇿🇬🇭🇪🇸🇪🇸🇻🇳🇳🇵 A warm welcome to our

0

9

22

0

3

12

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

7/7 This effort was possible thanks to the many dedicated collaborators @ArielleElkrief @AdamJSchoenfeld @alessi_joao @XinAnnWang @pecci_federica1 @GLambertiMD @victorrvaz @BarrichelloMd @DJPinato @ACortelliniMD @FSkoulidis @mvnegrao @AmbrogioLab and mentors @DrMarkAwad @Jia_Luo

1

0

12

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

Don’t miss the 🚨 @OncoAlert hematology round up from #EHA24 . Discussing 👇👇 ✅IMROZ ✅TP53m in CLL ✅APOLLO ✅ASC4FIRST ✅STARGLO✨

OncoAlert

@OncoAlert

2 months

Dear Colleagues, Welcome to this Hematology Round Up from #EHA24 WE have focused on on Hematologic malignancies with abstracts presented on June 15nd, 2024 The first presentation was abstract s100 This Phase 3 study results of isatuximab, bortezomib, lenalidomide, and

0

8

23

0

4

13

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 month

👇🏻👇🏻👇🏻

OncoAlert

@OncoAlert

1 month

The @IASLC 's expert panel offers 1⃣9⃣ new recommendations in Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable🫁 #NSCLC including: 1️⃣ Multidisciplinary evaluation 2️⃣ Biomarker testing 🎯 3️⃣ Neoadjuvant chemoimmunotherapy for stage III 4️⃣ Strategies for stage II

0

24

28

0

2

10

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

The complete @OncoAlert 🚨 coverage of #ASCO24 is coming soon 📨📨📨. To get it for free in your inbox, register at: or … Don't miss out!

The OncoAlert Newsletter

The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!

oncoalert.m-pages.com

OncoAlert

@OncoAlert

2 months

The @OncoAlert 🚨COVERAGE For the COMPLETE #ASCO24 Congress is COMING SOON and DELIVERED TO YOU IN YOUR INBOX REGISTER at or ✅NADINA in #Melanoma ✅CROWN👑in #LungCancer ✅EVOKE01🫁 ✅LAURA ✅ADRIATIC🌊 ✅ESOPEC ✅TRANSMET

0

16

53

0

5

11

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

The @OncoAlert 🚨ROUND UP Covering May 2-8, 2024 👇👇👇 REGISTER at OR …

The OncoAlert Newsletter is NOW OUT Click to Register

The OncoAlert Newsletter is now out for June 23-29, 2023

www.oncoalert360.com

OncoAlert

@OncoAlert

3 months

The OncoAlert🚨ROUND UP Covering May 2-8, 2024 REGISTER at OR ✅ @TheLancet Commission on #ProstateCancer ✅DESTINY-PanTumor01 ✅MONARCH3 🦋in #BreastCancer

0

21

33

0

4

10

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

The @OncoAlert 🚨 coverage of #ESMOBreast24 is coming soon 📨📨. To get it for free in your inbox, register at: or …

The OncoAlert Newsletter

The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!

oncoalert.m-pages.com

OncoAlert

@OncoAlert

3 months

The @OncoAlert 🚨COMPLETE COVERAGE of #ESMOBreast24 🇩🇪is COMING ✉️REGISTER TO GET IT at or Covering: ✅IMPASSION132💊 ✅CAPITELLO291 ✅PF-07220060 ✅TROPION-BREAST01 ✅BRCA BCY🤰 ✅NATALEE ✅CARABELA ✅MORPHEUS-PAN BC ✅HER2DX🧬

1

26

59

0

3

10

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

@PTarantinoMD This reminds me also of #IMG & international board certified MDs explaining to the US Boards of Medicine why their 10-12 years of training count 😅. @GRecondoMD @alessi_joao @PTarantinoMD @darioT_ @victorrvaz @thenasheffect

2

0

10

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

6/7 KRAS G12D define a subtype of KRASmt NSCLC with distinct co-mutations, a colder/excluded TME, and worse outcomes to PD-(L)1 blockade. Studies of KRASmt NSCLC should factor this into analysis and trial design. Check out for additional information.

1

0

9

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

5/7 We next explored outcomes to PD-(L)1 blockade therapy and found that patients with KRAS G12D NSCLC had significantly lower ORR, PFS, and OS to PD-(L)1 monotherapy but not chemo-immunotherapy, compared to KRAS non-G12D NSCLC.

1

3

9

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

The @OncoAlert 🚨newsletter covering June 13-20, 2024 is OUT. Register at or … to receive it directly in your inbox 📨📨📨

The OncoAlert Newsletter is NOW OUT Click to Register

The OncoAlert Newsletter is now out for June 23-29, 2023

www.oncoalert360.com

OncoAlert

@OncoAlert

2 months

The @OncoAlert 🚨Newsletter OUT Covering June 13-20, 2024 REGISTER at or Discussing: ✅🫁 #LungCancer Screening In US🇺🇸 ✅CORE 001💉in NMI #BladderCancer ✅Industry Update CAPItello 290 ✅ Amplifying Patient Voice in Clinical

0

12

28

0

2

9

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 years

@GLambertiMD @GRecondoMD @thenasheffect @KartikSehgal_MD @Deepti_Venkat @DrJNaidoo & @DrMarkAwad

Jarushka Naidoo

@DrJNaidoo

4 years

Emerging data on association btwn irAEs & ICI response, this time in SCLC. In our paper of 189 pts: - 22.9% had irAEs - analyzed as a time-varying covariate, irAEs associate with improved PFS & OS in SCLC @BiagioMd @HopkinsThoracic @RCSI_Irl #LCSM

0

4

31

0

1

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

@christine_lovly @GRecondoMD @DanaFarber Thank you so much @christine_lovly ! This also recognizes our amazing collaborators and colleagues who supported our efforts over the last few years. @ArielleElkrief @ACortelliniMD @thenasheffect @XinAnnWang @alessi_joao (among many others!)

1

0

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

7/7 This collaborative effort co-led w/ @MaugeriSacca @DrMarkAwad @marcomazz88 @stescalera was possible thanks to dedicated and talented investigators @gcaravagna @alessi_joao @GLambertiMD @DiFedericoMD @pecci_federica1 , and many others! @myESMO @DanaFarberNews #LCSM

1

2

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 years

#7PhotosOfMyLife no captions, no people. I was challenged by our outstanding mentor @DrMarkAwad . Day 2 of 7. Today, I invite Joao Alessi ⁦⁦ @alessi_joao ⁩

0

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

The 🚨 @OncoAlert newsletter is out!! Covering May 2-8, 2024. #OncoAlertAF 👇 REGISTER at OR …

The OncoAlert Newsletter

The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!

oncoalert.m-pages.com

OncoAlert

@OncoAlert

3 months

The OncoAlert🚨NEWSLETTER OUT Covering May 2-8, 2024 REGISTER at OR ✅ @TheLancet Commission on #ProstateCancer ✅DESTINY-PanTumor01 ✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁 ✅ASCENT in Triple Negative

0

26

35

0

1

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

The @OncoAlert 🚨NEWSLETTER OUT Covering May 17-23 , 2024 👇 Don’t forget to REGISTER at OR …

The OncoAlert Newsletter is NOW OUT Click to Register

The OncoAlert Newsletter is now out for June 23-29, 2023

www.oncoalert360.com

OncoAlert

@OncoAlert

2 months

The OncoAlert🚨NEWSLETTER OUT Covering May 17-23 , 2024 REGISTER at OR Discussing: ✅ICI’s 💉for POLE or POLD1 in met CRC ✅Advancements in mgt of Synchronous CRC Liver Mets ✅5yr outcome w/pembro💉 mono NSCLC🫁 ✅SBRT☢️ in Lung

0

21

54

0

1

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

@GRecondoMD Team effort!! @alessi_joao @GRecondoMD @GLambertiMD @pecci_federica1 @victorrvaz @BarrichelloMd #IMG

0

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

2/7 Among KRASmt NSCLC, KRAS G12D defines a subset with a lower pack-year smoking history, lower PD-L1 expression, and lower tumor mutational burden (TMB).

1

8

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 years

#7PhotosOfMyLife no captions, no people. I was challenged by our outstanding mentor @DrMarkAwad . Day 3 of 7. Today, I invite David Pinato ⁦⁦ @DJPinato ⁩

1

0

7

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

4/7 Importantly, compared to KRAS non-G12D NSCLC, KRAS G12D NSCLCs had also fewer CD8+ PD1+ T cells, and total PD-L1+ cells by multiplexed immunofluorescence.

1

7

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

@geoff_oxnard @rohit_thum @MSKCancerCenter @DanaFarber @MDAndersonNews Agree! This is a recurrent theme. As our group and the @FoundationOne team have reported, a very high TMB (>20 mut/Mb) can be a powerful tool to help guiding treatment decisions.

High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade

This cohort study examines the association between increasing tumor mutation burden (TMB) levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in...

jamanetwork.com

0

3

7

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

7 months

Special thanks to @alessi_joao , @XinAnnWang @SantagataLab , @JiaRenLin , @renato_umeton and @DrMarkAwad for their contribution to this study, and to @sitcancer for funding this project.

0

6

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

7 months

This effort, co-led with @GLambertiMD , was possible thanks to our patients, their families, and wonderful collaborators at @DanaFarber & @BrighamWomens : @lfspurr @pecci_federica1 @DiFedericoMD @malini_gandhi , @BarrichelloMd , @lmsholl @Deepti_Venkat @victorrvaz & many others!

2

0

6

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

The @OncoAlert NEWSLETTER is OUT! Don't miss it! Covering May 9-16 , 2024 REGISTER at OR …

The OncoAlert Newsletter

The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!

oncoalert.m-pages.com

OncoAlert

@OncoAlert

3 months

The OncoAlert🚨NEWSLETTER OUT Covering May 9-16 , 2024 REGISTER at OR Discussing: ✅CheckMate77T #LungCancer 🫁 ✅IMpassion132 #BreastCancer #ESMOBreast24 ✅MARS2 ✅DESTINY-Gastric01 #GastricCancer ✅KEYNOTE-057🔑 #BladderCancer

1

16

38

0

1

6

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

3/7 Compared to KRASmt non-G12D NSCLC (KRAS non-G12D), KRAS G12D NSCLC is characterized by an enrichment in NKX2-1 (TTF-1) and CDKN2A mutations.

1

6

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 months

The new @OncoAlert 🚨 newsletter is OUT! Don’t miss it! And if you don’t have a subscription, register at for the latest in oncology.

The OncoAlert Newsletter

The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!

oncoalert.m-pages.com

OncoAlert

@OncoAlert

3 months

The OncoAlert🚨NEWSLETTER OUT Covering April 25 to May 1, 2024 REGISTER at OR COVERING ✅DESTINY-Breast06 ✅Monarch E🦋 ✅ US Preventive S Task force #BreastCancer Screen ✅ @US_FDA 🇺🇸approval of Tisotumab vedotin ✅NEO

0

17

32

0

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

4 years

#7PhotosOfMyLife no captions, no people. I was challenged by our outstanding mentor ⁦⁦⁦ @DrMarkAwad ⁩. Day 1 of 7. Today, I invite Deepti Venkatraman ⁦⁦ @Deepti_Venkat ⁩

1

0

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 year

@ACortelliniMD @thenasheffect @M_Tagliamento Ahaha I guess we are the photo boomers 😅

1

0

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 months

Led by the Taek-Chin Cheong - @chiarlelab w/ @alessi_joao @DiFedericoMD @DrMarkAwad & many others @DFarberThoracic @BostonChildrens @ALKPositiveinc @ros1cancer @RETpositive @NTRKers

0

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

3/7 Using transcriptomic data from the TCGA, we found that LUADs w/ KEAP1 C-LOH mut had lower enrichment scores of TNF-α, NF-kB and JAK/STAT pathways, and were also associated w/ immune-desert (D) tumor microenvironment (TME), compared to KEAP1 CD-SC mut and KEAP1 WT cases.

1

0

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

1 month

@OncoAlert #GUARDSymposium2024 @tompowles1

OncoAlert

@OncoAlert

1 month

Just Out at DAY 2⃣ #GUARDSymposium2024 @OncoAlert 🚨Faculty @tompowles1 🇬🇧 Future strategies in adjuvant Muscle Invasive #BladderCancer Pinging: @cdanicas @nataliagandur @g_develasco @mjuanfi81 @drenriquegrande @dralvaropinto @bavilima @T_AlonsoGordoa @yekeduz_emre

0

19

26

0

2

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

3 years

@victorrvaz @DanaFarber @BrighamWomens Congrats on submitting your application! And thank you for all your hard work!! @alessi_joao @BarrichelloMd @DrMarkAwad @ACortelliniMD @DJPinato

2

0

5

Biagio Ricciuti, MD PhD

@BiagioRicciutMD

2 years

4/7 By using multiplexed immunofluorescence, we confirmed that LUADs with KEAP1 C-LOH mut have significantly lower intratumoral CD8+ T cells, and PD-L1 expression on tumor cells, compared to LUADs with KEAP1 CD-SC mut, and KEAP1 WT genotype.